Paper39400342
The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.
Rencuzogullari A and 13 others. J Surg Oncol, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy. Papers, record 39400342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39400342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Stomach Neoplasms | Major topic |
| Neoadjuvant Therapy | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Adenocarcinoma | Major topic |
| Perioperative Care | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Docetaxel | |
| Epirubicin | |
| Propensity Score | |
| Leucovorin | |
| Aged | |
| Retrospective Studies | |
| Fluorouracil | |
| Oxaliplatin | |
| Survival Rate | |
| Gastrectomy | |
| Follow-Up Studies | |
| Chemotherapy, Adjuvant | |
| Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| The authors received no specific funding for this work. | PubMed |
Source PubMed
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37015332 | Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 | https://conductscience.org/library/papers/37015332 | PubMed |
| 2 | 29566109 | Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/29566109 | PubMed |
| 3 | 30174850 | Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. | J Thorac Dis | 2018 | https://conductscience.org/library/papers/30174850 | PubMed |
| 4 | 37963317 | Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/37963317 | PubMed |
| 5 | 32487637 | Hydro-MDCT for Gastric Adenocarcinoma Staging. A Comparative Study With Surgical and Histopathological Findings for Selecting Patients for Echo-endoscopy. | Anticancer Res | 2020 | https://conductscience.org/library/papers/32487637 | PubMed |
| 6 | 15383798 | Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. | Ann Surg | 2004 | https://conductscience.org/library/papers/15383798 | PubMed |
| 7 | 33024393 | Artificial intelligence in gastric cancer: Application and future perspectives. | World J Gastroenterol | 2020 | https://conductscience.org/library/papers/33024393 | PubMed |
| 8 | 31582518 | ctDNA in Gastric and Gastroesophageal Cancer: Prognostic, Predictive, or Preliminary? | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31582518 | PubMed |
| 9 | 23213098 | Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23213098 | PubMed |
| 10 | 10655437 | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/10655437 | PubMed |
| 11 | 16822992 | Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16822992 | PubMed |
| 12 | 33798955 | Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. | Cancer Treat Rev | 2021 | https://conductscience.org/library/papers/33798955 | PubMed |
| 13 | 31109837 | The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer. | Urol Oncol | 2019 | https://conductscience.org/library/papers/31109837 | PubMed |
| 14 | 22734012 | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. | Ann Oncol | 2012 | https://conductscience.org/library/papers/22734012 | PubMed |
| 15 | 35535555 | MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. | Future Oncol | 2022 | https://conductscience.org/library/papers/35535555 | PubMed |
| 16 | 30982686 | Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. | Lancet | 2019 | https://conductscience.org/library/papers/30982686 | PubMed |
| 17 | 38134948 | Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. | Lancet Oncol | 2024 | https://conductscience.org/library/papers/38134948 | PubMed |
| 18 | 35876385 | CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison. | Ann Surg | 2022 | https://conductscience.org/library/papers/35876385 | PubMed |
| 19 | 32040809 | Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. | J Gastrointest Surg | 2021 | https://conductscience.org/library/papers/32040809 | PubMed |
| 20 | 36842787 | Gastric adenocarcinoma: A review of the TNM classification system and ways of spreading. | Radiologia (Engl Ed) | 2023 | https://conductscience.org/library/papers/36842787 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882832 | Neoadjuvant Advantage, Adjuvant Challenge: Clinical Evidence and Hypothetical Biological Mechanisms Behind Divergent Tolerability. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882832 | PubMed |
| 42812350 | Gastric cancer and the TNT era: have we solved the timing question, or only redistributed the treatment? | Front Oncol | 2026 | https://conductscience.org/library/papers/42812350 | PubMed |
| 42057888 | Safety and feasibility of total neoadjuvant FLOT chemotherapy in locally-advanced gastric and gastroesophageal junction cancer. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42057888 | PubMed |
| 42038345 | Pretreatment C-reactive protein-triglyceride-glucose index predicts survival in patients with FLOT-treated locally advanced gastric and gastroesophageal junction cancer. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42038345 | PubMed |
| 41859180 | Perioperative chemotherapy (FLOT 4 + 4) versus total neoadjuvant therapy (TNT; FLOT ×8) for resectable gastric cancer: A systematic review and exploratory meta-analysis. | Surg Open Sci | 2026 | https://conductscience.org/library/papers/41859180 | PubMed |
| 41787276 | The role of GP73 in predicting overall survival and chemotherapy response in locally advanced gastric cancer: a retrospective cohort study. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/41787276 | PubMed |
| 41753172 | Predicting the Unpredictable: Prognostic Role of Systemic Inflammatory Indices and Tumor Biology of Neoadjuvant Chemotherapy Response in Gastric and Gastroesophageal Junction Cancer-Insights from a Systematic Review and Real-World Experience. | J Clin Med | 2026 | https://conductscience.org/library/papers/41753172 | PubMed |
| 40962962 | Is More Really Better? Intensive Neoadjuvant Therapy and Standard Perioperative FLOT for Locally Advanced Gastric Cancer Demonstrate Similar Short-Term Outcomes. | Ann Surg Oncol | 2025 | https://conductscience.org/library/papers/40962962 | PubMed |
| 40115020 | Perioperative versus adjuvant chemotherapy for resectable gastric cancer: a meta-analysis of randomized controlled trials. | Front Oncol | 2025 | https://conductscience.org/library/papers/40115020 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39400342
GET https://conductscience.org/api/papers/v1/39400342/references?page=2